Does DURVALUMAB Cause Immune-mediated enterocolitis? 165 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 165 reports of Immune-mediated enterocolitis have been filed in association with DURVALUMAB (IMFINZI). This represents 1.0% of all adverse event reports for DURVALUMAB.
165
Reports of Immune-mediated enterocolitis with DURVALUMAB
1.0%
of all DURVALUMAB reports
40
Deaths
91
Hospitalizations
How Dangerous Is Immune-mediated enterocolitis From DURVALUMAB?
Of the 165 reports, 40 (24.2%) resulted in death, 91 (55.2%) required hospitalization, and 31 (18.8%) were considered life-threatening.
Is Immune-mediated enterocolitis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DURVALUMAB. However, 165 reports have been filed with the FAERS database.
What Other Side Effects Does DURVALUMAB Cause?
Death (2,817)
Malignant neoplasm progression (1,330)
Pneumonitis (827)
Radiation pneumonitis (786)
Pyrexia (573)
Diarrhoea (530)
Pneumonia (453)
Dyspnoea (444)
Interstitial lung disease (430)
Off label use (395)
What Other Drugs Cause Immune-mediated enterocolitis?
NIVOLUMAB (1,289)
IPILIMUMAB (988)
PEMBROLIZUMAB (858)
CARBOPLATIN (307)
PACLITAXEL (188)
ATEZOLIZUMAB (156)
LENVATINIB (143)
PEMETREXED (129)
BEVACIZUMAB (92)
TREMELIMUMAB\TREMELIMUMAB-ACTL (63)
Which DURVALUMAB Alternatives Have Lower Immune-mediated enterocolitis Risk?
DURVALUMAB vs DUTASTERIDE
DURVALUMAB vs DUTASTERIDE\TAMSULOSIN
DURVALUMAB vs DUVELISIB
DURVALUMAB vs DYDROGESTERONE
DURVALUMAB vs EBASTINE